WebEMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer. Elacestrant is a novel, nonsteroidal, orally … WebApr 21, 2024 · The phase 3 POTOMAC trial [ 115, 116] will assess whether the addition of durvalumab to standard-of-care BCG, after complete resection of papillary tumors, improves DFS compared with BCG alone. Table 2 Summary of ongoing and planned key durvalumab trials in early-stage bladder cancer, hepatocellular carcinoma and cervical cancer
Elacestrant (oral selective estrogen receptor degrader) …
WebJun 6, 2024 · The EMERALD Phase 3 trial is a randomized, open label, active-controlled study evaluating elacestrant as second- or third-line monotherapy in ER+/HER2- advanced/metastatic breast cancer... WebApr 7, 2024 · Targeted Oncology TM: What did the updated data from the phase 3 EMERALD trial (NCT03778931) investigating elacestrant (Orserdu) show for patients with metastatic estrogen receptor–positive, HER2-negative breast cancer?. HURVITZ: In the update at the 2024 San Antonio Breast Cancer Symposium [SABCS], they did analysis … colstrip public schools colstrip mt
Results from EMERALD trial and key findings from PI3K pathway …
WebDec 9, 2024 · Elacestrant May Improve Outcomes for Patients Whose Metastatic Breast Cancers Progressed on Prior Endocrine Therapy. Elacestrant is the first oral selective … WebOct 15, 2024 · The Company is pursuing a comprehensive clinical trial programme that includes Imfinzi as a single treatment and in combination with tremelimumab and other novel antibodies in multiple tumour types, stages of disease, and lines of treatment, and where relevant using the PD-L1 biomarker as a decision-making tool to define the best potential … WebJun 2, 2024 · Methods: EMERALD (NCT03778931) is a randomized, open-label, phase 3 trial that enrolled patients with ER+/HER2− mBC who had 1–2 lines of endocrine therapy, mandatory pretreatment with a CDK4/6 inhibitor, and ≤1 chemotherapy. Patients were randomized 1:1 to elacestrant (400 mg orally daily) or SOC (investigator’s choice of … dr. thamer wisam